Zentalis Pharmaceuticals (ZNTL) Assets Average (2020 - 2026)
Zentalis Pharmaceuticals (ZNTL) posted quarterly Assets Average of $271.0 million for Q1 2026, down 33.44% year-over-year from $407.2 million in Q1 2025, and down 12.04% quarter-over-quarter from $308.1 million in Q4 2025.
Zentalis Pharmaceuticals (ZNTL) Assets Average (2020 - 2026) Analysis & Trends
Zentalis Pharmaceuticals' Assets Average history runs 7 years deep, the most recent figure standing at $271.0 million for Q1 2026.
- In Q1 2026, Assets Average fell 33.44% year-over-year to $271.0 million; the TTM figure through Mar 2026 stood at $271.0 million (down 33.44% YoY), while the FY2025 annual figure was $359.7 million, down 26.75% from the prior year.
- Assets Average for Q1 2026 stood at $271.0 million, down from $308.1 million in the prior quarter.
- The five-year high for Assets Average was $603.6 million in Q3 2023, with the low at $271.0 million in Q1 2026.
- The 5-year median for Assets Average is $486.8 million (2022), against an average of $466.2 million.
- The sharpest annual moves came in 2022 and 2026: Assets Average jumped 58.99% in 2022, then slumped 33.44% in 2026.
- Zentalis Pharmaceuticals' Assets Average stood at $534.3 million in 2022, then gained by 6.45% to $568.7 million in 2023, then decreased by 22.54% to $440.5 million in 2024, then sank by 30.05% to $308.1 million in 2025, then dropped by 12.04% to $271.0 million in 2026.
- Business Quant data shows ZNTL's Assets Average at $271.0 million in Q1 2026, $308.1 million in Q4 2025, and $339.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Zentalis Pharmaceuticals | 255.14 Mn | 255.14 Mn | - | 234.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 234.20 Mn |
| Mar 31, 2026 | 271.02 Mn |
| Dec 31, 2025 | 308.11 Mn |
| Sep 30, 2025 | 339.48 Mn |
| Jun 30, 2025 | 367.86 Mn |
| Mar 31, 2025 | 407.18 Mn |
| Dec 31, 2024 | 440.50 Mn |
| Sep 30, 2024 | 471.17 Mn |
| Jun 30, 2024 | 524.58 Mn |
| Mar 31, 2024 | 554.58 Mn |
| Dec 31, 2023 | 568.70 Mn |
| Sep 30, 2023 | 603.58 Mn |
| Jun 30, 2023 | 555.39 Mn |
| Mar 31, 2023 | 514.33 Mn |
| Dec 31, 2022 | 534.25 Mn |
| Sep 30, 2022 | 548.52 Mn |
| Jun 30, 2022 | 486.77 Mn |
| Mar 31, 2022 | 430.09 Mn |
| Dec 31, 2021 | 444.79 Mn |
| Sep 30, 2021 | 359.52 Mn |